Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
nesvacumab · 2 trials · 1 indication
Determine the maximum tolerable dose or recommended phase 2 dose of nesvacumab (REGN910/ SAR307746) administered in combination with aflibercept (ziv-aflibercept) in patients with advanced solid malignancies
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | - |
| Cohort 2 | EXPERIMENTAL | - |
| Cohort 3a | EXPERIMENTAL | - |
| Cohort 3b | EXPERIMENTAL | - |
| Cohort 4 | EXPERIMENTAL | - |
| Cohort 3 | EXPERIMENTAL | Dose 3 |
| Cohort 5 | EXPERIMENTAL | Dose 5 |
| Expansion Cohort 1 | EXPERIMENTAL | Dose 4 |
| Expansion Cohort 2 | EXPERIMENTAL | Dose 5 |
| Name | Type | Description |
|---|---|---|
| nesvacumab (REGN910/ SAR307746) | DRUG | Dose level 1 |
| aflibercept (ziv-aflibercept) | DRUG | Dose level 1 |
Inclusion Criteria: Inclusion criteria include, but are not limited to, the following: 1. Confirmed diagnosis of solid tumor malignancy 2. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 3. Adequate hepatic, renal and bone marrow function 4. Resolution of toxicity from prior th...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Nesvacumab is an investigational monoclonal antibody developed by Regeneron Pharmaceuticals, Inc. (ticker: REGN) for the treatment of solid tumors. It is an ANGPT2 inhibitor that has been studied in Phase 1 clinical trials in patients with advanced solid malignancies.
Nesvacumab has been studied for the treatment of solid tumors in adults. Both of its Phase 1 trials enrolled patients with advanced solid malignancies, and one trial evaluated nesvacumab in combination with aflibercept, known as Ziv-aflibercept in the United States.
Nesvacumab targets ANGPT2, also known as angiopoietin-2. It is an ANGPT2 inhibitor monoclonal antibody. By binding ANGPT2, nesvacumab is designed to interfere with angiopoietin-2 signaling, a pathway involved in tumor angiogenesis and vascular biology.
Nesvacumab is developed by Regeneron Pharmaceuticals, Inc., which trades under the ticker REGN. The drug is also identified by the code names REGN910 and SAR307746, reflecting its development history.
Nesvacumab is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. Both of its Phase 1 trials in solid tumors are listed as completed, and no trials are currently active.
Nesvacumab has been evaluated in two completed Phase 1 trials. NCT01688960 studied nesvacumab with aflibercept in advanced solid malignancies and enrolled 48 patients. NCT01271972 studied nesvacumab alone in solid tumors and enrolled 53 patients. Both trials were conducted in the United States and Canada.
Yes. Nesvacumab is also known as REGN910 and SAR307746. REGN910 is Regeneron's internal code for the antibody, while SAR307746 reflects the compound's designation under a collaboration with Sanofi. All three names refer to the same ANGPT2 inhibitor monoclonal antibody.